Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs) Meeting Abstract
| Authors: | Carles, J.; Davis, I.; De Bono, J. S.; Fizazi, K.; Gerritsen, W.; Rathkopf, D. E.; Ryan, C. J.; Saad, F.; Steuber, T.; Wilding, G.; Park, Y. C.; Charnas, R.; De Porre, P.; Van Poppel, H. |
| Abstract Title: | Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA + P) for ≥ 4 years (yrs) |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi251 |
| Language: | English |
| ACCESSION: | WOS:000393912500737 |
| DOI: | 10.1093/annonc/mdw372.24 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 740P -- Source: Wos |
